Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | PTPRC | P08575 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29472298 | 1.00 | CYP2A6 (0.46) | CYP2A6HTR2CHTR2AMEN1KMT2A | |
| SCHEMBL4187399 | 0.83 | APP (0.38) | CYP2A6HTR2CHTR2AMEN1KMT2A | |
| SCHEMBL15389974 | 0.79 | CYP2A6 (0.50) | CYP2A6HTR2CHTR2AMEN1KMT2A | |
| SCHEMBL13872151 | 0.79 | CYP2A6 (0.46) | CYP2A6HTR2CHTR2AMEN1KMT2A | |
| SCHEMBL10369397 | 0.79 | CYP2A6 (0.46) | CYP2A6HTR2CHTR2AMEN1KMT2A | |
| SCHEMBL20419214 | 0.79 | HTR2C (0.46) | CYP2A6HTR2CHTR2AMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL11180431 | 0.78 | CYP2A6 (0.48) | CYP2A6HTR2CHTR2AMEN1KMT2A | |
| SCHEMBL28483335 | 0.77 | SNCA (0.45) | CYP2A6HTR2CHTR2AMEN1KMT2A | |
| SCHEMBL9593575 | 0.76 | CA2 (0.48) | CYP2A6HTR2CHTR2AMEN1KMT2A | |
| SCHEMBL17740782 | 0.75 | ALDH1A1 (0.55) | CYP2A6MEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3832763-A1 | POSITIVE ELECTRODE ACTIVE MATERIAL FOR MAGNESIUM BATTERIES | FUJIFILM Wako Pure Chemical Corporation (JP) | 2021-06-09 | — | — | EP | disclosed |
| WO-2020160134-A1 | ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| EP-3480201-A1 | NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS | Oncostellae, S.L. (ES) | 2019-05-08 | — | — | EP | disclosed |
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
| US-20100273842-A1 | AMINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY AND THE USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2010-10-28 | — | — | US | disclosed |
| US-20100267945-A1 | AMINE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| US-20100216798-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | ASTELLAS PHARMA INC (JP) | 2010-08-26 | — | — | US | disclosed |
| US-20100216798-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | ASTELLAS PHARMA INC (JP) | 2010-08-26 | — | — | US | disclosed |
| EP-1960386-A2 | SUBSTITUTED CYCLOALKYLPYRROLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-27 | — | — | EP | disclosed |
| US-20070117808-A1 | Substituted Cycloalkylpyrrolones As Allosteric Modulators Of Glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-24 | — | — | US | disclosed |
| WO-2007053765-A2 | SUBSTITUTED CYCLOALKYLPYRROLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007013673-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2007-02-01 | — | — | WO | disclosed |
| EP-0878196-B1 | KAINIC ACID NEURONOTOXICITY INHIBITORS AND PYRIDOTHIAZINE DERIVATIVES | YAMANOUCHI PHARMA CO LTD (JP) | 2003-09-03 | — | — | EP | disclosed |
| US-6133258-A | PYRIDOTHIAZINE DERIVATIVE; FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS, MULTIPLE SCLEROSIS, PAIN, GLAUCOMA | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2000-10-17 | — | — | US | disclosed |
| EP-0878196-A1 | KAINIC ACID NEURONOTOXICITY INHIBITORS AND PYRIDOTHIAZINE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1998-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273842-A1 | AMINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY AND THE USES THEREOF | NPY5R, NPY1R, NPY2R | CYP2A6 2415/4885HTR2C 143/4885HTR2A 155/4885 |
| US-20170320870-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | CYP2A6 49/4885HTR2C 977/4885HTR2A 2443/4885 |
| US-20100267945-A1 | AMINE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | CYP2A6 1718/4885HTR2C 66/4885HTR2A 64/4885 |
| US-20070117808-A1 | Substituted Cycloalkylpyrrolones As Allosteric Modulators Of Glucokinase | GCKR, GCK, GALK1 | CYP2A6 757/4885HTR2C 2929/4885HTR2A 2708/4885 |
| US-20100317646-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | CYP2A6 46/4885HTR2C 919/4885HTR2A 2320/4885 |
| US-20100216798-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | LCK, ZAP70, FYN | CYP2A6 3973/4885HTR2C 3467/4885HTR2A 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.